<DOC>
	<DOCNO>NCT01394120</DOCNO>
	<brief_summary>In recent year , treatment advance pancreatic cancer change . Currently , several active schedule chemotherapy use , gemcitabine monotherapy combination capecitabine erlotinib , FOLFIRINOX . Moreover , development biomarker ( therapeutic target ) predicte response treatment new important tool use clinical practice select best scheme patient . Preliminary study show therapeutic target determination , use tumor tissue collect patient , could determine presence group `` chemotherapy responder '' . Such case EGFR amplification and/or K-Ras gene status correlation response erlotinib . Moreover , Thymidilate Synthase , Thimidine Phosphorylase , ERCC-1 Topoisomerase I expression immunohistochemistry GI tumor sample relate resistance response 5FU-capecitabine , oxaliplatin irinotecan respectively . Based data investigator design phase II clinical trial evaluate efficacy select treatment pancreatic cancer patient base determination therapeutic target . The therapeutic target-driven treatment efficacy compare prospective treatment control group patient treat discretion physician-researcher</brief_summary>
	<brief_title>Chemotherapy Selection Based Therapeutic Targets Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Study Phase : Phase 2 Trial Study Objetives : - Primary end-point . Proportion patient alive 12 month patient advance pancreatic carcinoma individually select group accord expression tumor tissue therapeutic target . - Secondary end-points . 1 . Assessing feasibility method patient-treatment-selection base tumor tissue expression therapeutic target . 2 . Overal survival comparison Gemcitabine single agent treatment rest chemotherapy schedule . 3 . Determination progression-free survival treatment group . 4 . Determination toxicity patient . Study population Number subject : A total 60 pancreatic cancer patient advance pancreas cancer previous systemic treatment expect enrol . Study design schedule . Patients randomize ( 1:1 ) control arm experimental treatment arm guide therapeutic target . In control arm , patient treat conventional chemotherapy regimens discretion investigator . In experimental arm , patient treat determined tumor tissue available biomarker TS , TP , ERCC-1 , Topo-1 , K-Ras mutation EGFR FISH , choose FOLFIRINOX schema , FOLFOX , FOLFIRI , Gemcitabine-Capecitabine Gemcitabine-Erlotinib , Gemcitabine single agent . All patient analyze intention treat</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<criteria>Histologic diagnosis pancreas adenocarcinoma Clinical stage IV Feasible patient chemotherapy Availability tumor tissue possibility tumor biopsy define therapeutic target Informed write consent Previous systemic treatment advance pancreas adenocarcinoma Contraindication administration drug use study : capecitabine , 5Fluouracil , irinotecan , oxaliplatin , gemcitabine erlotinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pancreas cancer</keyword>
	<keyword>Targeted Therapy</keyword>
</DOC>